press_release_conclusion: Combining radiotherapy and hormone therapy in patients with prostate cancer significantly improves men’s survival compared with hormone therapy treatment alone.
abstract_conclusion: The addition of RT to ADT improved overall survival at 7 years (74%, 95% CI 70–78 vs 66%, 60–70; hazard ratio [HR] 0·77, 95% CI 0·61–0·98, p=0·033).